COMPASS PATHWAYS PLC - AMERICAN DEPOSITORY SHARES

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

13 Dec 2021 06:00:02 By Nasdaq GlobeNewswire

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

03 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

01 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences

30 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways granted fifth US patent for crystalline psilocybin

23 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

09 Nov 2021 06:18:48 By Nasdaq GlobeNewswire

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

09 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce third quarter 2021 financial results on 9 November 2021

08 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

03 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

20 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways is granted new US patent for crystalline psilocybin

19 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences

21 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

14 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

10 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September

07 Sep 2021 09:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

11 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

04 Aug 2021 07:27:10 By Nasdaq GlobeNewswire

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

03 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer

29 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training

21 Jul 2021 06:00:00 By Nasdaq GlobeNewswire